These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27829541)

  • 1. Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey.
    Deegan P; Fernandez-Sasso D; Giraldo P; Lau H; Panahloo Z; Zimran A
    Blood Cells Mol Dis; 2018 Feb; 68():218-225. PubMed ID: 27829541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
    Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
    Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey.
    Lau H; Belmatoug N; Deegan P; Goker-Alpan O; Schwartz IVD; Shankar SP; Panahloo Z; Zimran A
    Blood Cells Mol Dis; 2018 Feb; 68():226-231. PubMed ID: 27839985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
    Cravo R; Rotman V; Oliveira PMN; Defendi HGT; Conceição DA; Xavier JR; Chertkoff R; Noronha TG; Maia MLS
    Blood Cells Mol Dis; 2018 Feb; 68():160-162. PubMed ID: 28131618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
    Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
    Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease.
    Elstein D; Abrahamov A; Oz A; Arbel N; Baris H; Zimran A
    Blood Cells Mol Dis; 2015 Dec; 55(4):415-8. PubMed ID: 26460268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
    Zimran A; Pastores GM; Tylki-Szymanska A; Hughes DA; Elstein D; Mardach R; Eng C; Smith L; Heisel-Kurth M; Charrow J; Harmatz P; Fernhoff P; Rhead W; Longo N; Giraldo P; Ruiz JA; Zahrieh D; Crombez E; Grabowski GA
    Am J Hematol; 2013 Mar; 88(3):172-8. PubMed ID: 23339116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24months.
    Ida H; Tanaka A; Matsubayashi T; Murayama K; Hongo T; Lee HM; Mellgard B
    Blood Cells Mol Dis; 2016 Jul; 59():140-7. PubMed ID: 27241455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
    Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
    Laudemann K; Moos L; Mengel E; Lollert A; Hoffmann C; Brixius-Huth M; Wagner D; Düber C; Staatz G
    Blood Cells Mol Dis; 2016 Mar; 57():35-41. PubMed ID: 26852653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.
    Pastores GM; Rosenbloom B; Weinreb N; Goker-Alpan O; Grabowski G; Cohn GM; Zahrieh D
    Genet Med; 2014 May; 16(5):359-66. PubMed ID: 24263462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan.
    Sagara R; Ishigaki M; Otsuka M; Murayama K; Ida H; Fernandez J
    Orphanet J Rare Dis; 2021 Dec; 16(1):502. PubMed ID: 34863216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
    Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
    Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS).
    Zimran A; Belmatoug N; Bembi B; Deegan P; Elstein D; Fernandez-Sasso D; Giraldo P; Goker-Alpan O; Lau H; Lukina E; Panahloo Z; Schwartz IVD;
    Am J Hematol; 2018 Feb; 93(2):205-212. PubMed ID: 29090476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.
    Serratrice C; Bengherbia M; Alessandrini M; Grosbois B; Camou F; Pers YM; Bismuth M; Marie I; Belmatoug N; Berger M;
    Blood Cells Mol Dis; 2014; 53(1-2):94-6. PubMed ID: 24411065
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.